logo
Popular Kids' Cough Medicine Recalled for Risk of Bacterial Infection That 'Can Cause Death'

Popular Kids' Cough Medicine Recalled for Risk of Bacterial Infection That 'Can Cause Death'

Yahoo6 hours ago

Medtech Products is recalling five lots of its Little Remedies Honey Cough Syrup for bacterial contamination
The food-borne illness causes gastrointestinal symptoms, which can be mild in healthy individuals but can cause death with long exposure
The recall also extends to any lots within expiryA popular cough medicine for children is being recalled for possible bacterial contamination.
Medtech Products issued a voluntary recall of five lots of its Little Remedies Honey Cough Syrup due to "the presence of Bacillus cereus and loss of shelf-stability," the United States Food and Drug Administration stated in an announcement on June 18. The product was distributed nationwide between Dec. 14, 2022, and June 4, 2025.
Bacillus cereus is a bacteria that can cause two kinds of foodborne illnesses, both related to gastrointestinal issues. The first illness is marked by nausea, vomiting and stomach cramps that begin anywhere from one to six hours after consuming the contaminated product. The second illness, which tends to begin eight to 16 hours after consuming the contaminated product, is marked by stomach cramps and diarrhea.
"Although healthy individuals may suffer only short term illness, exposure to high levels of foodborne B. cereus can cause death," the announcement read.
The recall extends to Little Remedies Honey Cough Syrup in a 4 fl oz amber bottle with a UPC of 7-56184-10737-9. The lots included in the recall are as follows:
Lot 0039, with an expiration date of 11/2025
Lot 0545, with an expiration date of 01/2026
Lot 0640, with an expiration date of 02/2026
Lot 0450, with an expiration date of 05/2026
Lot 1198, with an expiration date of 12/2026
Furthermore, all lots of the product that are still within expiry are included in the recall.
Customers who bought the recalled product are urged to stop using it immediately and contact a doctor in the event of any symptoms that could be associated with using the product. The company will also offer reimbursement to those who purchased items from the recalled lots.
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from juicy celebrity news to compelling human interest stories.
Medtech Products did not disclose how it discovered the bacterial contamination.
Any further questions or concerns should be directed to Medtech at medicalaffairs@prestigebrands.com, on their site, or by phone at (800) 754-8853.
Read the original article on People

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Blue state GOP lawmakers urge major healthcare change for illegal immigrants
Blue state GOP lawmakers urge major healthcare change for illegal immigrants

Fox News

time17 minutes ago

  • Fox News

Blue state GOP lawmakers urge major healthcare change for illegal immigrants

EXCLUSIVE: Colorado congressional Republicans are asking the state to stop allowing illegal immigrants to enroll in the state's Medicaid program, Health First Colorado. The program's availability to those in the country illegally who meet other requirements for coverage started this year, and the Republicans pitched changes in a letter to Democratic Gov. Jared Polis Wednesday. On Health First Colorado's website, it says, "Don't let immigration status stop you from applying for health coverage," citing state law. "Other Democrat-run states like California and Minnesota are beginning to walk back their policies that offer free and subsidized health care to illegal immigrants even without the One Big Beautiful Bill Act being law because they know that these policies are expensive, bad deals for their Medicaid beneficiaries," the letter from representatives Gabe Evans, Jeff Crank and Lauren Boebert states. "It is disheartening to see Colorado continue to double down and prioritize individuals who are unlawfully present even in the face of adverse impacts on Americans who need Medicaid the most, and we urge you to reverse course," the Republicans added. As the letter notes, Colorado is one of seven states that offer public healthcare coverage that does not factor in one's immigration status. California, Minnesota and Illinois are making reforms to their Medicaid offerings, according to The Wall Street Journal. Minnesota and Illinois are ending the availability as part of budget deals, and California is navigating different options, like a possible enrollment freeze, as its legislature hashes out a budget. In California, a recent poll revealed nearly 60% oppose Medicaid for illegal immigrants despite the law going into effect last year. The lawmakers added that the reconciliation bill includes a provision that will significantly penalize states that provide coverage to illegal immigrants because the Medicaid programs receive both federal and state taxpayer dollars. "There is a renewed urgency to revise this policy in light of the likely enactment of federal legislation to reduce the Medicaid [Federal Medical Assistance Percentage] for the expansion population from 90% to 80% for sanctuary states who use taxpayer dollars to cover illegal immigrants. As you know, this change would pose significant budgetary challenges to Colorado – but only if the state continues to pursue this policy," the letter states. A spokesperson for Polis' office told Fox News Digital in a statement that the reconciliation bill in the U.S. Senate should be completely redone from the House version. "Governor Polis is disappointed these three lawmakers are trying to gut Medicaid and kick people off private insurance, which would raise insurance costs for everyone who buys commercial insurance because of cost-shifting. Thanks to their votes — which they're trying to distract from — nearly 400,000 Coloradans would lose health care, which would also raise costs for everyone else," the statement said. "Governor Polis continues calling on the Senate to start from scratch with this terrible bill, including truly protecting Medicaid and extending critical subsidies for those who purchase plans off the health exchange so Coloradans can afford health care."

Leona Maguire, four back at KPMG, still dealing with aftermath of tick bites at Erin Hills
Leona Maguire, four back at KPMG, still dealing with aftermath of tick bites at Erin Hills

Yahoo

time28 minutes ago

  • Yahoo

Leona Maguire, four back at KPMG, still dealing with aftermath of tick bites at Erin Hills

FRISCO, Texas – Leona Maguire doesn't typically wear sun sleeves on the golf course. But, after suffering from several tick bites at the U.S. Women's Open at Erin Hills, the Irishwoman went on a round of doxycycline, and it has wreaked havoc on her skin. The medication is meant to reduce the chance of contracting Lyme disease, and she's just finished up the two-week treatment. She wore pants last week at the Meijer but couldn't bring herself to do it this week in steamy Texas. Advertisement 'It's made my skin like tissue paper,' said Maguire, who has a particularly nasty blood blister on her right hand that she said looks like a pepperoni. Her twin sister Lisa, who recently graduated from dental school, dressed the wound twice during Round 1 of the KPMG Women's PGA Championship. Maguire opened with an even-par 72 at Fields Ranch East course to sit four strokes back of leader Jeeno Thitikul. After four consecutive missed cuts, Maguire has found something with her driver after switching back to last year's model. She also went back to her old putter — almost. Maguire's Ping rep has always had a backup putter at his house that was identical to her longtime putter, and she asked him to bring it out to Texas this week. Advertisement For the last few weeks, she'd been trying a center-shafted putter. 'Sometimes, what do they say, a rest is as good as a change,' said Maguire. 'It's nice to have this familiar putter.' This article originally appeared on Golfweek: Leona Maguire still dealing with aftermath of tick bites at Erin Hills

Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut
Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut

Yahoo

time30 minutes ago

  • Yahoo

Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut

On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering. Housing market weakness triggers Lennar to offer biggest incentives since 2009 The Trump administration is trying to bring back asbestos How one company is revolutionizing the way we use everyday water The diagnostics company's IPO follows the successful debut of fintech companies like Chime Financial and Circle Internet Group, and will test whether investors are ready to embrace biotech companies despite declines in the sector for the last six months. Here's what to know about the listing. Founded in 2008 by David Dean Halbert, the healthcare company utilizes next-generation artificial intelligence (AI) and machine learning for precision medicine. Through molecular analysis, Caris specializes in cancer diagnosis and treatment. According to a recent filing to the Securities and Exchange Commission (SEC), the Irving, Texas-based company currently has over 1,700 employees and over 100 biopharmaceutical partners. The company incurred net losses of $281.9 million and $341.4 million in 2024 and 2023, respectively, on revenue of $412.3 million and $306.1 million. It is expecting additional losses in the future. Caris Life Sciences shares are expected to begin trading on Wednesday, June 18, with the offering expected to run through June 20. Caris Life Sciences will trade its stock under the ticker CAI. CAI shares were priced at $21, above their previously planned range. The IPO price was planned between the $19 and $20 range, up from the previous $16 and $18 planned price. The current pricing would value Caris Life Sciences at around $5.9 billion. CAI will trade its shared on the Nasdaq Global Select Market. Caris Life Sciences's IPO will offer 23,529,412 shares. Founder and CEO Halbert is also set to retain 41.7% of ownership following the IPO. This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store